FY27 revenue growth >40%
Management expects standalone revenue growth exceeding 40% in FY27, driven by Palar ramp-up and Egypt commissioning.
PLATINUM / guidance tracker
Keep management guidance in view.
Platinum Industries · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
35% CAGR from FY26 to FY29
Company targets a 35% compound annual growth rate over the next three years, excluding pharma business.
Egypt commercial production by September 2026
Egypt plant construction to complete by end of May 2026, pre-commissioning in June, commercial production by September 2026.
Pharma revenue in FY27
New pharma subsidiary (Rivardu Life Sciences) expected to generate revenue in FY27, though no specific figures provided.
FY27 Revenue Growth >40%
Management targets >40% revenue growth in FY27, with 10% from Egypt and rest from India.
35% CAGR from FY26 to FY29
Long-term revenue CAGR target of 35% over FY26-29, supported by Egypt ramp-up and new products.
Egypt Plant Commercial Ops in Q3 FY27
Egypt facility to start commercial production in Q3 FY27, contributing ~10% of FY27 revenue.
EBITDA Margin Maintained at 13-15%
Management expects to maintain EBITDA margin in 13-15% range in FY27.